company background image
PAR

Paradigm Biopharmaceuticals ASX:PAR Stock Report

Last Price

AU$2.14

Market Cap

AU$446.2m

7D

54.0%

1Y

11.2%

Updated

09 Aug, 2022

Data

Company Financials +
PAR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PAR Stock Overview

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia.

Paradigm Biopharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share PriceAU$2.14
52 Week HighAU$2.69
52 Week LowAU$0.85
Beta1.5
1 Month Change91.07%
3 Month Change75.41%
1 Year Change11.17%
3 Year Change50.18%
5 Year Change692.59%
Change since IPO478.38%

Recent News & Updates

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

PARAU BiotechsAU Market
7D54.0%0.1%0.7%
1Y11.2%-1.3%-8.0%

Return vs Industry: PAR exceeded the Australian Biotechs industry which returned -1.3% over the past year.

Return vs Market: PAR exceeded the Australian Market which returned -8% over the past year.

Price Volatility

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement12.3%
Biotechs Industry Average Movement11.7%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: PAR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PAR's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aMarco Polizzihttps://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Paradigm Biopharmaceuticals Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
PAR fundamental statistics
Market CapAU$446.24m
Earnings (TTM)-AU$40.55m
Revenue (TTM)AU$65.75k

7,643x

P/S Ratio

-12.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAR income statement (TTM)
RevenueAU$65.75k
Cost of RevenueAU$169.79k
Gross Profit-AU$104.03k
Other ExpensesAU$40.45m
Earnings-AU$40.55m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin-158.23%
Net Profit Margin-61,675.63%
Debt/Equity Ratio0%

How did PAR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAR?

Other financial metrics that can be useful for relative valuation.

PAR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5959.1x
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does PAR's PB Ratio compare to its peers?

PAR PB Ratio vs Peers
The above table shows the PB ratio for PAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2x
OPT Opthea
3.3x32.8%AU$478.9m
MSB Mesoblast
0.8x64.2%AU$604.4m
BNO Bionomics
1.2x-13.0%AU$70.4m
IMM Immutep
2.6x62.9%AU$285.9m
PAR Paradigm Biopharmaceuticals
8.4x39.2%AU$446.2m

Price-To-Book vs Peers: PAR is expensive based on its Price-To-Book Ratio (9.5x) compared to the peer average (2x).


Price to Earnings Ratio vs Industry

How does PAR's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Book vs Industry: PAR is expensive based on its Price-To-Book Ratio (9.5x) compared to the Australian Biotechs industry average (3x)


Price to Book Ratio vs Fair Ratio

What is PAR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PAR's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PAR (A$2.14) is trading above our estimate of fair value (A$0.29)

Significantly Below Fair Value: PAR is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Paradigm Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


39.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PAR is forecast to have no revenue next year.

High Growth Revenue: PAR is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PAR is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Paradigm Biopharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PAR is currently unprofitable.

Growing Profit Margin: PAR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAR is unprofitable, and losses have increased over the past 5 years at a rate of 45.8% per year.

Accelerating Growth: Unable to compare PAR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: PAR has a negative Return on Equity (-76.63%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Paradigm Biopharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PAR's short term assets (A$63.9M) exceed its short term liabilities (A$14.0M).

Long Term Liabilities: PAR's short term assets (A$63.9M) exceed its long term liabilities (A$613.7K).


Debt to Equity History and Analysis

Debt Level: PAR is debt free.

Reducing Debt: PAR has no debt compared to 5 years ago when its debt to equity ratio was 0%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.9% each year


Discover healthy companies

Dividend

What is Paradigm Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PAR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Marco Polizzi

0.083

Tenure

Mr. Marco Polizzi has been an Executive Vice President of Commercial Operations at Casper Pharma LLC since May 23, 2016. Mr. Polizzi served as the Head of Sales & Marketing, Institutional at Sandoz Pharmac...


Leadership Team

Experienced Management: PAR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PAR's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Paradigm Biopharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Paradigm Biopharmaceuticals Limited
  • Ticker: PAR
  • Exchange: ASX
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$446.245m
  • Shares outstanding: 234.25m
  • Website: https://www.paradigmbiopharma.com

Location

  • Paradigm Biopharmaceuticals Limited
  • 500 Collins Street
  • Level 15
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.